放疗前血浆转化生长因子-β1水平与肺癌患者的长期预后相关。
Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma.
作者信息
Kong F, Jirtle R L, Huang D H, Clough R W, Anscher M S
机构信息
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
出版信息
Cancer. 1999 Nov 1;86(9):1712-9.
BACKGROUND
Plasma transforming growth factor-beta1 (TGFbeta1) levels are increased in many malignancies at the time of diagnosis, including all forms of lung carcinoma. Therefore, the potential use of TGFbeta1 as a plasma marker to predict the long term outcome of lung carcinoma patients treated with radiotherapy (RT) was evaluated.
METHODS
Plasma samples for 59 newly diagnosed lung carcinoma patients were assayed for TGFbeta1 before RT (pre RT), at the end of RT (end RT), and during follow-up after RT. TGFbeta1 was extracted from plasma using an acid-ethanol method. An enzyme-linked immunoadsorbent assay was used to quantify the plasma TGFbeta1 levels. The normal value for this assay is < or =7.5 ng/mL. Disease status at last follow-up was without knowledge of TGFbeta1 levels. Comparisons within groups and between groups were estimated using analysis of variance and the Student t test for unpaired data, respectively.
RESULTS
The 59 patients were divided into 2 groups according to their disease status at last follow-up: those with no evidence of disease (NED) (n = 13) and those with disease (WD) (n = 46). The median follow up was 26.8 months and 12.4 months, respectively, for the NED and WD groups. No significant differences were found in the clinical characteristics between the two groups. The plasma TGFbeta1 level before RT was significantly higher in the WD group (mean +/- standard error of the mean [SEM] = 12.5+/-1.7 ng/mL; median = 8.6 ng/mL) compared with the NED group (mean +/- SEM = 6.0+/-1.0 ng/mL; median = 6.0 ng/mL) (P = 0.037). At the time of last follow-up, WD patients had a significantly higher plasma TGFbeta1 level (mean +/- SEM = 11.6+/-1.3 ng/mL; median = 9.6 ng/mL) compared with NED patients (mean +/- SEM = 3.7+/-0.5 ng/mL; median = 3.6 ng/mL) (P = 0.002).
CONCLUSIONS
These data demonstrate that plasma TGFbeta1 may be a useful tumor marker in patients with lung carcinoma.
背景
在包括所有类型肺癌在内的许多恶性肿瘤确诊时，血浆转化生长因子β1（TGFβ1）水平会升高。因此，评估了TGFβ1作为血浆标志物预测接受放射治疗（RT）的肺癌患者长期预后的潜在用途。
方法
对59例新诊断的肺癌患者的血浆样本在放疗前（RT前）、放疗结束时（RT结束时）以及放疗后的随访期间进行TGFβ1检测。采用酸乙醇法从血浆中提取TGFβ1。使用酶联免疫吸附测定法对血浆TGFβ1水平进行定量。该测定法的正常值为≤7.5 ng/mL。末次随访时的疾病状态不了解TGFβ1水平。组内和组间比较分别采用方差分析和非配对数据的Student t检验进行评估。
结果
59例患者根据末次随访时的疾病状态分为两组：无疾病证据（NED）组（n = 13）和有疾病（WD）组（n = 46）。NED组和WD组的中位随访时间分别为26.8个月和12.4个月。两组的临床特征无显著差异。与NED组（均值±均值标准误[SEM]=6.0±1.0 ng/mL；中位数=6.0 ng/mL）相比，WD组放疗前的血浆TGFβ1水平显著更高（均值±SEM = 12.5±1.7 ng/mL；中位数=8.6 ng/mL）（P = 0.037）。在末次随访时，与NED患者（均值±SEM = 3.7±0.5 ng/mL；中位数=3.6 ng/mL）相比，WD患者的血浆TGFβ1水平显著更高（均值±SEM = 11.6±1.3 ng/mL；中位数=9.6 ng/mL）（P = 0.002）。
结论
这些数据表明血浆TGFβ1可能是肺癌患者有用的肿瘤标志物。
Zotero 插件